Compare Kimberly Clark Corp (KMB) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Summit Therapeutics Inc — how do they compare? Kimberly Clark Corp trades at $107.37 (market cap $36.01B), while Summit Therapeutics Inc trades at $14.4 (market cap $10.48B). The key difference: Kimberly Clark Corp is far larger — about 3.4× Summit Therapeutics Inc's market cap, and Kimberly Clark Corp pays a 4.72% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| KMB | SMMT | |
|---|---|---|
Market Cap | $36.01B | $10.48B |
Sector | Consumer Staples | Health |
52-Week High | $136.77 | $29.32 |
52-Week Low | $93.05 | $13.05 |
Enterprise Value | $42.55B | $9.90B |
Dividend Yield | 4.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $108.43, up 0.07% on the day, with a neutral technical signal and bullish moving averages. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.97 exceeding the $1.93 estimate. Revenue declined to $16.45B in 2025, but net income margin remains strong at 12.8%. Recent news highlights KMB's innovation strategy and its status as a Dividend King, with a 4.5% yield attracting income investors.
KMB offers stable income with a high dividend yield and solid fundamentals, but faces revenue pressure and competitive risks. Analyst consensus is a $115.33 price target with a hold-heavy rating. Key risks include consumer sentiment impacts and input cost inflation, while the pending Kenvue merger provides growth potential.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
